Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn Pharmaceuticals has recruited 30% of the patients in a randomized, double blind, placebo-controlled study Phase IIb clinical trial to evaluate Serdaxin as a treatment for major depressive disorder (MDD).
Subscribe to our email newsletter
The study calls for recruiting up to 300 patients and is being conducted at approximately 40 sites in the US.
Enrollment for the Phase IIb trial was initiated in January 2011.
The primary endpoint of the study is the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS).
Rexahn Pharma president Rick Soni said they are pleased with the rapid progress in Serdaxin’s Phase IIb trial enrollment.
"We remain on track to complete enrollment in the first half of 2011, with preliminary results expected in late 2011," Soni said.